XKRX
016580
Market cap140mUSD
Oct 08, Last price
10,180.00KRW
1D
0.00%
1Q
1.80%
Jan 2017
-35.77%
Name
Whanin Pharm Co Ltd
Chart & performance
P/E
13.84
P/S
0.74
EPS
735.51
Div yield, %
2.95%
Shrs. gr., 5y
4.03%
Rev. gr., 5y
8.25%
Revenues
255.21b
-1.69%
Net income
13.60b
-41.85%
CFO
9.04b
-56.30%
Dividend
Dec 29, 2025300 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Whan In Pharm Co.,Ltd. is a South Korean pharmaceutical enterprise specializing in the research, development, manufacturing, promotion, and distribution of therapeutic products. Their comprehensive portfolio encompasses treatments for mental health conditions (such as antidepressants and antipsychotics), neurological disorders (including nootropics, anti-dementia, and anti-epileptics), cardiovascular and gastrointestinal ailments, infectious diseases, allergies, pain and inflammation, metabolic imbalances, respiratory issues, and a variety of other central nervous system applications. Established in 1978, the company's corporate headquarters are situated in Seoul, South Korea.
Key people
Gye Gwan Lee
Vice Chairman · since 2012
Byeong Yeon Yoo
Vice President, Director · since 2010
Byeong Rak Ahn
Managing Director
Jong Su Kim
Managing Director · since 2010
Yun Bae Kim
Managing Director
Seung Won Lee
Assistant Managing Director
Dong Su Lee
Assistant Managing Director
Seung Sik Lee
Assistant Managing Director
Won Beom Lee
President, Co-Chief Executive Officer, Director · since 2012
Gwang Su Ha
Non-Executive Independent Director · since 2013
Sang Won Hwang
Non-Executive Independent Director · since 2022
Gi Ok Jang
Non-Executive Independent Director · since 2010
Byeong Mu Lee
Non-Executive Independent Director · since 2013
Jeom Gyu Lee
Non-Executive Independent Director · since 2020
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||